Evidence map›Paper›PMID 42080361›Full record

Trial reportFuture oncology (London, England)2026

Impact of

Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M O'Reilly, Zev A Wainberg and 1 more

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04083235 (An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04083235 phase3completednot on this map

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas

TypeinterventionalSponsorIpsenRan2020 to 2025Enrolled770ConditionsMetastatic Adenocarcinoma of the PancreasArmsIrinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maen AbdelrahimInstitute for Academic Medicine, Houston Methodist Cancer Center, Houston, TX, USA.
Gazala KhanDepartment of Hematology-Oncology, Henry Ford Hospital, Detroit, MI, USA.
Hassan HatoumDepartment of Hematology/Oncology, Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Alice ZervoudakisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Farshid DayyaniChao Family Comprehensive Center, University of California, Irvine, Orange, CA, USA.ORCID 0000-0002-4970-5189
Li ZhangIpsen, Cambridge, MA, USA.
Jia LiIpsen, Cambridge, MA, USA.
Fiona MaxwellIpsen, London, UK.
Eileen M O'ReillyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8076-9199
Zev A WainbergDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Andrea BullockDepartment of Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0001-7143-0225

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

aimsTo evaluate the effect of

methodsThis pre-specified exploratory analysis evaluated safety outcomes by

resultsAmong 749 treated patients, 83 were homozygous for

conclusionsCLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT04083235; EudraCT 2018-003585-14.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalGlucuronosyltransferasePancreatic NeoplasmsAdultAgedFemaleFluorouracilGenotypeHumansIrinotecanLeucovorinMaleMiddle AgedOxaliplatinPaclitaxelFluorouracilGlucuronosyltransferaseIrinotecanLeucovorinOxaliplatinPaclitaxelUGT1A1 Enzymehomozygousliposomal irinotecanMetastatic pancreatic ductal adenocarcinoma (mPDAC)NALIRIFOXNAPOLI 3SN-38UGT1A1*28

Identifiers

PMID42080361
PMCPMC13203033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.